Evaluation of
| Autor: | Xing, Zhou, Xiao, Jiang, Luzhou, Liu, Xiaoxiong, Wang, Chuan, Li, Yutang, Yao, Ying, Kou, Jiaqi, Shen, Taipeng, Shen, Zeng, Li, Shengke, Yang, Shukui, Zhou, Hong, Liao, Zhifu, Luo, Xiaoai, Wu, Shirong, Chen, Zhuzhong, Cheng |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Translational Oncology |
| ISSN: | 1936-5233 |
| Popis: | Highlights • 18F-PSMA-1007 PET/CT demonstrated a high detection rate for PCa patients with a raised PSA level after radical prostatectomy. PSMA-positive lesions were detected in 56 (56/71, 79%) patients. The detection efficacy for patients with PSA level >2.0 ng/mL, 1.1 to ≤2.0 ng/mL, 0.51 ng/mL to ≤1.0 ng/mL and ≤0.5 ng/mL was 100% (28/28), 100% (8/8), 80% (4/5) and 50% (14/28), respectively. • Patients with ADT were more likely to have a high detection rate. The detection rate for patients with ADT was 84.6% (33/39), and detection rate for patients only receive RP was 66.7% (16/24). • Higher Gleason score (≤7 vs. ≥8) leads to higher detection rate. The detection rate for patients with Gleason score ≥8 was 88.9% (32/36), detection rate for patients with Gleason score ≤7 was 58.3% (14/24). Purpose Prostate-specific membrane antigen (PSMA) ligands targeting has shown promising results in staging of prostate cancer (PCa). The aim of present study was to evaluate the value of 18F-PSMA-1007 PET/CT in PCa patients with biochemical recurrence. Methods 71 patients with PCa after radical prostatectomy (RP) were included in the present study. Median prostate-specific antigen (PSA) level was 1.27 ng/mL (range 0.01–67.40 ng/mL, n = 69). All patients underwent whole-body PET/CT imaging after injection of 333±38 MBq 18F-PSMA-1007. The distribution of PSMA-positive lesions was assessed. The influence of PSA level, androgen deprivation therapy and primary Gleason score on PSMA-positive finding and uptake of 18F-PSMA-1007 were evaluated. Results 56 (79%) patients showed at least one pathological finding on 18F-PSMA-1007 PET/CT. The rates of positive scans were 50%, 80%, 100%, 100% among patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and >2.0 ng/mL, respectively. The median Gleason score was 8 (range 7–10), and higher Gleason score (≤7 vs. ≥8) leads to higher detection rates (58.3% (14/24) vs. 88.9% (32/36), P = 0.006). The median SUVmax of positive findings in patients with PSA levels ≤0.5, 0.51–1.0, 1.1–2.0 and >2.0 ng/mL were 4.51, 4.27, 11.50 and 14.08, respectively. The median SUVmax in patients with PSA level >2.0 ng/mL was significantly higher than that in patients with PSA ≤2.0 ng/mL (14.08 vs. 6.13, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|